The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 9, 2006, Pages 2337-2340

  Hu, Lain Yen ^a   Boxer, Peter A ^a   Kesten, Suzanne R ^a   Lei, Huangshu J ^a   Wustrow, David J ^a   Moreland, David W ^a   Zhang, Liming ^a   Ahn, Kay ^a   Ryder, Todd R ^a   Liu, Xiaohong ^a   Rubin, John R ^a   Fahnoe, Kelly ^a   Carroll, Richard T ^a   Dutta, Satavisha ^a   Fahnoe, Douglass C ^a   Probert, Albert W ^a   Roof, Robin L ^a   Rafferty, Michael F ^a   Kostlan, Catherine R ^a   Scholten, Jeffrey D ^a   Hood, Molly ^a   Ren, Xiao Dan ^a   Schielke, Gerald P ^a   Su, Ti Zhi ^a   Taylor, Charles P ^a   Mistry, Anil ^a   McConnell, Patrick ^a   Hasemann, Charles ^a   Ohren, Jeffrey ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE INHIBITOR; BRANCHED CHAIN AMINO ACID AMINOTRANSFERASE; GLUTAMIC ACID;

AMINO ACID TRANSPORT; AREA UNDER THE CURVE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; IC 50; IN VIVO STUDY; NERVE CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOFURANS; CALCIUM; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GLUTAMIC ACID; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; NEURONS; RATS; RATS, INBRED LEW; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRANSAMINASES;

EID: 33644986624     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.07.058     Document Type: Article

References (18)

1. S. Hutson, D. Berkich, P. Drown, B. Xu, M. Aschner, and K. LaNoue J. Neurochem. 71 1998 863
2. T. Hall, R. Wallin, G. Reinhart, and S. Hutson J. Biol. Chem. 268 1993 3092
3. J. Davoodi, P. Drown, R. Bledsoe, R. Wallin, G. Reinhart, and S. Hutson J. Biol. Chem. 273 1998 4982
4. N. Kholodilov, M. Neystat, T. Oo, S. Hutson, and R. Burke Mol. Brain Res. 75 2000 281
5. E. Lieth, K. LaNoue, D. Berkich, B. Xu, M. Ratz, C. Taylor, and S. Hutson J. Neurochem. 76 2001 1712
6. P. Jouvet, P. Rustin, D.L. Taylor, J.M. Pocock, U. Felderhoff-Mueser, N.D. Mazarakis, C. Sarraf, U. Joashi, M. Kozma, K. Greenwood, A.D. Edwards, and H. Mehmet Mol. Biol. Cell 11 2000 1919
7. 4b The amount of GDH was determined for each preparation to ensure the saturating level for the assay;
8. P. O'Carra, T. Griffin, M. O'Flaherty, N. Kelly, and P. Mulcahy Biochim. Biophys. Acta 1297 1996 235
9. Inhibitors were solubilized in DMSO at a primary concentration of 10 mM and then diluted to give a final concentration between 0.3 and 100 μM. The assay is done in a 96-well plate. Total reaction volume of 100 μl consisted of 58 μl reaction mixture with 2μl of specified inhibitor and 38 μl water. The reaction was started with 2 μl BCAT enzyme. The 96-well reaction plate was incubated for 30 min at 37°C. The reaction was stopped with 100μl of 2% acetic acid (1% Final) and analyzed for glutamate with LC/MS/MS.
10. 45Ca uptake was determined thirty minutes following the addition of LPDC. Cultures were washed trice with 500 ml HBSS and then dissolved with lysate buffer. Individual lysates were combined with 10 ml scintillation cocktail and counted for emissions using a Tricarb 2900TR Packard Liquid Scintillation Analyzer;
11. F.W. Marcoux, and A.W. Probert Stroke 19 1988 148
12. J.B. Schulz, R.T. Matthews, T. Klockgether, J. Dichgans, and M.F. Beal Mol. Cell. Biochem. 174 1997 193
13. 11 For evaluation of brain damage, sections were examined with a light microscope for detecting positive staining black areas that implied areas of neuronal death. Total number of sections with the positive findings from each group was finally compared with other groups (Newman-Keuls).
14. 6) δ 7.44 (dd, 1H, J = 9.04 and 2.20 Hz), 7.53 (s, 1H), 7.63 (d, 1H, J = 8.79 Hz), 7.75-7.82 (m, 2H), 7.84 (d, 1H, J = 1.95 Hz), 7.93 (dd, 1H, J = 2.2 and 9.03 Hz), 8.13 (dd, 1H, J = 2.44 and 6.59 Hz), 10.19 (s, 1H), and 11.06 (s, 1H);
15. Hu, L.-Y.; Kesten, S.R.; Lei, H.; Wustrow, D.J.; Ryder, T.R.E.P. EP 1,314,723, 2003.
16. Tripos Associates, St. Louis, MO;
17. Coordinates have been deposited with the RCSB Protein Data Bank with the ID cods 2ABJ.
18. R.C. Switzer Toxicol. Pathol. 28 2000 70